Geode Capital Management LLC Increases Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Geode Capital Management LLC grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 4.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,138,292 shares of the biotechnology company's stock after acquiring an additional 44,277 shares during the period. Geode Capital Management LLC owned about 2.55% of United Therapeutics worth $401,184,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. National Wealth Management Group LLC bought a new stake in United Therapeutics during the fourth quarter worth about $209,000. Franklin Resources Inc. raised its stake in shares of United Therapeutics by 31.4% in the fourth quarter. Franklin Resources Inc. now owns 329,379 shares of the biotechnology company's stock worth $116,218,000 after purchasing an additional 78,660 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of United Therapeutics by 28.5% during the fourth quarter. Alliancebernstein L.P. now owns 709,043 shares of the biotechnology company's stock valued at $250,179,000 after buying an additional 157,363 shares during the last quarter. Axiom Investors LLC DE increased its holdings in United Therapeutics by 9.3% in the 4th quarter. Axiom Investors LLC DE now owns 10,040 shares of the biotechnology company's stock worth $3,543,000 after buying an additional 853 shares in the last quarter. Finally, AIA Group Ltd bought a new position in United Therapeutics during the 4th quarter valued at about $215,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the transaction, the executive vice president now owns 36,781 shares of the company's stock, valued at approximately $11,261,606.58. The trade was a 23.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Raymond Dwek sold 4,000 shares of the stock in a transaction that occurred on Monday, April 7th. The stock was sold at an average price of $284.55, for a total value of $1,138,200.00. Following the completion of the transaction, the director now owns 1,750 shares of the company's stock, valued at $497,962.50. The trade was a 69.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 87,500 shares of company stock valued at $30,640,680 over the last quarter. 11.90% of the stock is currently owned by insiders.

Remove Ads

Analysts Set New Price Targets

Several brokerages have recently weighed in on UTHR. HC Wainwright reiterated a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. StockNews.com downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. Finally, UBS Group raised their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $388.25.

United Therapeutics Stock Down 6.7 %

Shares of NASDAQ UTHR traded down $19.66 during trading hours on Thursday, hitting $273.12. 175,747 shares of the stock were exchanged, compared to its average volume of 451,334. The firm has a fifty day moving average price of $326.18 and a 200-day moving average price of $352.23. United Therapeutics Co. has a 12 month low of $230.39 and a 12 month high of $417.82. The company has a market cap of $12.27 billion, a PE ratio of 12.06, a PEG ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the prior year, the company earned $4.36 earnings per share. As a group, equities analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.